Leevi
ALStuttu:n jäsen
Uudessa tutkimuksessa ALS-lääke rilutsolin tehoa testattiin kolmella eri hiirimallilla. Se ei pidentänyt hiirten elinikää.
Tutkijat toteavat vapaasti suomennettuna: "Rilutsolia määrätään ALS-potilaille laajasti huolimatta sen tehoon liittyvistä kysymyksistä. Tuloksemme viittaavat siihen että jos rilutsoli tunnistettaisiin nykyisin lääke-ehdokkaaksi, se ei etenisi esikliinistä tutkimusta pidemmälle. Tämä nostaa kysymyksiä esikliinisessä vaiheessa käytettyjen standardien osalta ALS:n hoidossa."
https://www.ncbi.nlm.nih.gov/pubmed/29221425
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Dec 8:1-8. doi: 10.1080/21678421.2017.1407796. [Epub ahead of print]
Riluzole does not improve lifespan or motor function in three ALS mouse models.
Hogg MC1, Halang L1, Woods I1, Coughlan KS1, Prehn JHM1.
Abstract
BACKGROUND:
Riluzole is the most widespread therapeutic for treatment of the progressive degenerative disease amyotrophic lateral sclerosis (ALS). Riluzole gained FDA approval in 1995 before the development of ALS mouse models. We assessed riluzole in three transgenic ALS mouse models: the SOD1G93A model, the TDP-43A315T model, and the recently developed FUS (1-359) model.
METHODS:
Age, sex and litter-matched mice were treated with riluzole (22 mg/kg) in drinking water or vehicle (DMSO) from symptom onset. Lifespan was assessed and motor function tests were carried out twice weekly to determine whether riluzole slowed disease progression.
RESULTS:
Riluzole treatment had no significant benefit on lifespan in any of the ALS mouse models tested. Riluzole had no significant impact on decline in motor performance in the FUS (1-359) and SOD1G93A transgenic mice as assessed by Rotarod and stride length analysis.
CONCLUSIONS:
Riluzole is widely prescribed for ALS patients despite questions surrounding its efficacy. Our data suggest that if riluzole was identified as a therapeutic candidate today it would not progress past pre-clinical assessment. This raises questions about the standards used in pre-clinical assessment of therapeutic candidates for the treatment of ALS.
Tutkijat toteavat vapaasti suomennettuna: "Rilutsolia määrätään ALS-potilaille laajasti huolimatta sen tehoon liittyvistä kysymyksistä. Tuloksemme viittaavat siihen että jos rilutsoli tunnistettaisiin nykyisin lääke-ehdokkaaksi, se ei etenisi esikliinistä tutkimusta pidemmälle. Tämä nostaa kysymyksiä esikliinisessä vaiheessa käytettyjen standardien osalta ALS:n hoidossa."
https://www.ncbi.nlm.nih.gov/pubmed/29221425
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Dec 8:1-8. doi: 10.1080/21678421.2017.1407796. [Epub ahead of print]
Riluzole does not improve lifespan or motor function in three ALS mouse models.
Hogg MC1, Halang L1, Woods I1, Coughlan KS1, Prehn JHM1.
Abstract
BACKGROUND:
Riluzole is the most widespread therapeutic for treatment of the progressive degenerative disease amyotrophic lateral sclerosis (ALS). Riluzole gained FDA approval in 1995 before the development of ALS mouse models. We assessed riluzole in three transgenic ALS mouse models: the SOD1G93A model, the TDP-43A315T model, and the recently developed FUS (1-359) model.
METHODS:
Age, sex and litter-matched mice were treated with riluzole (22 mg/kg) in drinking water or vehicle (DMSO) from symptom onset. Lifespan was assessed and motor function tests were carried out twice weekly to determine whether riluzole slowed disease progression.
RESULTS:
Riluzole treatment had no significant benefit on lifespan in any of the ALS mouse models tested. Riluzole had no significant impact on decline in motor performance in the FUS (1-359) and SOD1G93A transgenic mice as assessed by Rotarod and stride length analysis.
CONCLUSIONS:
Riluzole is widely prescribed for ALS patients despite questions surrounding its efficacy. Our data suggest that if riluzole was identified as a therapeutic candidate today it would not progress past pre-clinical assessment. This raises questions about the standards used in pre-clinical assessment of therapeutic candidates for the treatment of ALS.